重大事件
即時報告
8-K
2026-06-04
Neurogene Inc. 報告股東投票結果 8-K 申報
AI 繁中摘要
Neurogene Inc. 於 2026 年 6 月 4 日向 SEC 提交了一份 8-K 表格，報告 2026 年 6 月 3 日舉行的股東投票結果（Item 5.07）。該公司為一家製藥企業（SIC 2834），總部位於紐約，主要專注於基因治療及罕見中樞神經系統疾病藥物研發。是次申報僅披露股東大會已就若干事項進行投票，但並未於本摘要中列明具體議案、贊成或反對票數等細節。投資者應查閱完整申報文件（編號 0001404644-26-000040）以了解投票事項對公司管治及未來發展的潛在影響。📄
展開英文正文
EDGAR Filing Documents for 0001404644-26-000040 SEC.gov EDGAR Latest Filings Filings search tools Filing Detail SEC Home » Company Search » Current Page Form 8-K - Current report: SEC Accession No. 0001404644-26-000040 Filing Date 2026-06-04 Accepted 2026-06-04 16:41:02 Documents 11 Period of Report 2026-06-03 Items Item 5.07: Submission of Matters to a Vote of Security Holders Interactive Data Document Format Files Seq Description Document Type Size 1 8-K ngne-20260603.htm iXBRL 8-K 38619 Complete submission text file 0001404644-26-000040.txt 157564 Data Files Seq Description Document Type Size 2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ngne-20260603.xsd EX-101.SCH 1788 3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ngne-20260603_lab.xml EX-101.LAB 22548 4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ngne-20260603_pre.xml EX-101.PRE 13050 14 EXTRACTED XBRL INSTANCE DOCUMENT ngne-20260603_htm.xml XML 2802 Mailing Address 535 W 24TH STREET 5TH FLOOR NEW YORK NY 10011 Business Address 535 W 24TH STREET 5TH FLOOR NEW YORK NY 10011 (877) 237-5020 Neurogene Inc. (Filer) CIK: 0001404644 (see all company filings) EIN.: 980542593 | Fiscal Year End: 1231 Type: 8-K | Act: 34 | File No.: 001-36327 | Film No.: 261065615 SIC: 2834 Pharmaceutical Preparations (CF Office: 03 Life Sciences)